Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyCaicun Zhou, Changxuan You, Changli Wang et al.|The Lancet Oncology|2011Cited by 4.1k
Early detection of lung cancer by using an autoantibody panel in Chinese populationShengxiang Ren, Fred R. Hirsch, Shucai Zhang et al.|OncoImmunology|2017Cited by 203
Clinical Characteristics and Outcomes of Patients with Primary Lung Adenocarcinoma Harboring ALK Rearrangements Detected by FISH, IHC, and RT-PCRJinghui Wang, Shucai Zhang|PLoS ONE|2014Cited by 58
A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)Xingsheng Hu, Yan Sun, Baohui Han et al.|Lung Cancer|2014Cited by 51
Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A prospective observational studyHongge Liang, Mengzhao Wang, Xia Song et al.|Thoracic Cancer|2019Cited by 26